PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a obtaining to the paperwork reduction Act of 1995, no persons are required to respond to a obtain a valid OMB control number.									
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known					
				Application Number	10/829,042				
				Filing Date	April 21, 2004				
				First Named Inventor	Trevor Barrowcliffe				
				Art Unit	1652				
				Examiner Name	Hope A. Robinson				
Sheet	1	of	1	Attorney Docket Number	674583-2001				

		NON PATENT LITERATURE DOCUMENTS		
		de name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		ABSTRACT: M. Shima, et al., The Current Situation And Vision Of Plasma Protein Formulation, Biomedical Perspectives (1999) Vol. 8, No. 1, p. 99-107	1	
		ABSTRACT: A. Yoshioka, Recombinant Factor VIII, 8. Recombinant Factor VIII Formuation, Jap. J. Transfus. Med. (1992) Vol. 38, No. 6, p. 845-849	1	
		ABSTRACT: M. Arai, The Current Situation And Vision Of Plasma Protein; Biomed. Perspect. (1999) Vol. 9, No. 1, p. 108-117	1	

	Signature	Considered							
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not								
considered. Include copy of this form with next communication to applicant.									

Date

Examiner

considered. Include copy of this form with next contrainment of appearant to a proper of the contrainment of the proper of the contrainment of the contrainment of the proper of the proper